首页> 美国卫生研究院文献>Springer Open Choice >Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

【2h】

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

机译：绝经前内分泌反应性乳腺癌患者每隔3个月每2个月和3年或更长时间服用醋酸亮丙瑞林联合他莫昔芬辅助内分泌治疗的生活质量比较：一项随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe conducted an open-label, randomized controlled trial evaluating the appropriate treatment duration of leuprorelin acetate 3-month depot, TAP-144-SR (3M), administered postsurgically every 3 months for 2 years versus 3 or more (up to 5) years, in combination with tamoxifen, for 5 years in premenopausal endocrine-responsive breast cancer patients and reported similar survival benefit in the two treatment groups. We hereby present patient-reported quality of life (QOL) data obtained from this trial.

机译：背景我们进行了一项开放标签，随机对照试验，评估醋酸亮丙瑞林3个月长的制剂TAP-144-SR（3M）的适当治疗持续时间，每3个月进行术后2年（3年或以上（最多5年））联合他莫昔芬治疗绝经前内分泌反应性乳腺癌患者已有5年，并且在两个治疗组中报告了相似的生存获益。我们在此提供从该试验获得的患者报告的生活质量（QOL）数据。

著录项

期刊名称 Springer Open Choice
作者
Yasuo Ohashi; Eiichi Shiba; Hiroko Yamashita; Junichi Kurebayashi; Shinzaburo Noguchi; Hirotaka Iwase; Michihiro Yoshida; Tsukasa Fujimoto;
展开▼
作者单位

展开▼
年(卷),期 -1(26),3
年度 -1
页码 933–945
总页数 13
原文格式 PDF
正文语种
中图分类外科学;
关键词
Premenopausal endocrine-responsive breast cancer Adjuvant endocrine therapy Leuprorelin acetate Luteinizing hormone-releasing hormone agonist Quality of life;

机译：绝经前内分泌反应性乳腺癌;辅助内分泌治疗;醋酸亮丙瑞林;促黄体生成素的激素释放激素激动剂;生活质量;

相似文献

外文文献
中文文献
专利

1. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial [J] . Ohashi Yasuo, Shiba Eiichi, Yamashita Hiroko, Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer . 2018,第3期

机译：2年和3岁尿液蛋白醋酸蛋白的生命质量比较，每3个月储存与Tamoxifen在先生响应乳腺癌患者中的佐剂内分泌治疗组合：随机对照试验
2. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5?years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [J] . Junichi Kurebayashi, Eiichi Shiba, Tatsuya Toyama, Breast cancer . 2021,第3期

机译：随机对照研究评估Leuprorelin醋酸甘油蛋白的安全性和功效2与三个月为3或更多年的疗效，以5〜3或更多年在预氧化患者中辅助治疗患者的内分泌反应乳腺癌
3. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5?years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [J] . Eiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, Breast cancer . 2016,第3期

机译：一项随机对照研究，评估乙酸内洛瑞林每3个月贮存期为2对比3年或3年以上与他莫昔芬治疗5年的安全性和有效性，作为绝经前内分泌反应性乳腺癌患者的辅助治疗
4. ROLE OF ENDOCRINE DISRUPTOR CHEMICALS ON THE TISSUE LEVELS OF AHR AND SEX STEROID RECEPTORS IN PREMENOPAUSAL BREAST CANCER PATIENTS : COMPARISON WITH BENIGN FEMALE TUMOURS [C] . Sepideh Arbabi Bidgoli International Conference on Endocrine Disruptors . 2012

机译：内分泌干扰化学品对前肢乳腺癌患者AHR和性类固醇受体组织水平的作用：与良性女性肿瘤的比较
5. Analysis of quality of life data from a clinical trial in patients with advanced breast cancer with a comparison of different statistical approaches. [D] . Liu, Jianhua. 2002

机译：通过比较不同统计方法对晚期乳腺癌患者的临床试验的生活质量数据进行分析。
6. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [O] . Eiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, -1

机译：一项随机对照研究评估绝经前内分泌敏感型乳腺癌患者每隔3个月每3个月醋酸醋酸亮丙瑞林储库2年3年或3年以上与他莫昔芬5年作为辅助治疗的安全性和有效性
7. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer [O] . Eiichi Shiba, Hiroko Yamashita, Junichi Kurebayashi, 2015

机译：一项随机对照研究，评估绝经前内分泌敏感型乳腺癌患者每隔3个月每3个月醋酸醋酸亮丙瑞林储库2年，3年或3年以上与他莫昔芬5年作为辅助治疗的安全性和有效性

Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅